The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

@inproceedings{Fouqueray2013TheEA,
  title={The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy},
  author={Pascale Fouqueray and Valdis Pīrāgs and Silvio E. Inzucchi and Clifford J Bailey and Guntram Schernthaner and Michaela Diamant and Harold E. Lebovitz},
  booktitle={Diabetes care},
  year={2013}
}
OBJECTIVE A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg twice a day) or placebo added to a stable dose of metformin (1,500-2,000 mg/day). Change in A1C from baseline was the primary efficacy outcome; secondary outcomes included fasting plasma glucose… CONTINUE READING
8 Citations
8 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Similar Papers

Loading similar papers…